Scorpion Therapeutics
Part of Eli Lilly and Company
CompanyUnited StatesFounded 2020
Scorpion Therapeutics develops one asset, in phase 1 (Tersolisib in renal insufficiency). Mostly small molecule; based in the United States, founded in 2020.
- 1
- Asset
- Furthest stage
- Phase 1
- Raised
- $445M
- 1
- Trial
- 3
- Signals
Pipeline
1Selectively inhibits mutant PI3K alpha, blocking signaling that supports tumor growth.
Phase 1, Small molecule, renal insufficiency
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Funding rounds and grants4
- People15
- Signals3
- Similar companies6